FML FORTE (fluorometholone) by AbbVie is corticosteroid hormone receptor agonists [moa]. First approved in 1986.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
FML FORTE (fluorometholone) is a potent topical ophthalmic corticosteroid that acts as a corticosteroid hormone receptor agonist to reduce inflammation in the eye. It is formulated as a suspension for direct ocular application and treats inflammatory eye conditions including allergic conjunctivitis, uveitis, and post-operative inflammation. The drug works by binding corticosteroid receptors to suppress immune-mediated inflammation in ocular tissues.
Late-stage mature product with modest commercial activity signals smaller brand teams focused on maintenance and managed decline.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
FML FORTE offers limited career growth opportunities as a mature, low-activity ophthalmic product in late-stage lifecycle with minimal linked job openings. Roles available are primarily defensive, focused on maintaining market position and managing generic/competitive erosion rather than driving growth initiatives.
Worked on FML FORTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo